Meta-analysis: The effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine

BMJ Open

Volumn 4, Issue 3, 2014, Pages

  Tsuda, Yoshiyuki ^a   Saruwatari, Junji ^a   Yasui Furukori, Norio ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DSM-IV; HUMAN; ICD-10; META ANALYSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SMOKING; SYSTEMATIC REVIEW; TREATMENT DURATION; COMPLICATION; FEMALE; MALE;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SMOKING;

EID: 84897561176     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004216     Document Type: Article

References (52)

1. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-88. (Pubitemid 46686464)
2. Bishara D, Olofinjana O, Sparshatt A, et al. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 2013;33:329-35.
3. Si TM, Zhang YS, Shu L, et al. Use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the china psychotropic prescription studies. Clin Psychopharmacol Neurosci 2012;10:99-104.
4. Bersani FS, Capra E, Minichino A, et al. Factors affecting interindividual differences in clozapine response: a review and case report. Hum Psychopharmacol 2011;26:177-87.
5. Morisano D, Wing VC, Sacco KA, et al. Effects of tobacco smoking on neuropsychological function in schizophrenia in comparison to other psychiatric disorders and non-psychiatric controls. Am J Addict 2013;22:46-53.
6. Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. Smoking and schizophrenia. Psychiatr Danub 2009;21:371-5.
7. Citrome L, Stauffer VL, Chen L, et al Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 2009;29:278-83.
8. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003;23:119-27. (Pubitemid 36368788)
9. Schwenger E, Dumontet J, Ensom MH. Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clin Pharmacokinet 2011;50:415-28.
10. Liu HC, Chang WH, Wei FC, et al. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 1996;18:200-7.
11. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 2000;148:83-9. (Pubitemid 30062476)
12. Mauri M, Volonteri LS, Fiorentini A, et al. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res 2004;66:197-8. (Pubitemid 38041122)
13. McCarthy RH. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 1994;27:210-11. (Pubitemid 24291953)
14. Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit 1999;21:580-2. (Pubitemid 29468329)
15. Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002;17:141-3. (Pubitemid 34442196)
16. Brownlowe K, Sola C. Clozapine toxicity in smoking cessation and with ciprofloxacin. Psychosomatics 2008;49:176. (Pubitemid 351364993)
17. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 2011;39:91-2.
18. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12. (Pubitemid 30214957)
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
20. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
21. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006;62:1049-53. (Pubitemid 44786497)
22. Nozawa M, Ohnuma T, Matsubara Y, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008;30:35-40. (Pubitemid 351161096)
23. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008;48:157-65.
24. Laika B, Leucht S, Heres S, et al. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2009;10:20-9.
25. Spina E, D'Arrigo C, Santoro V, et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit 2009;31:758-63.
26. Skogh E, Sjodin I, Josefsson M, et al. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011;31:4-9.
27. Haslemo T, Refsum H, Molden E. The effect of ethinylestradiolcontaining contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Br J Clin Pharmacol 2011;71:611-l5.
28. Dettling M, Sachse C, Brockmoller J, et al. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology (Berl) 2000;152:80-6.
29. Palego L, Biondi L, Giannaccini G, et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:473-80. (Pubitemid 34252940)
30. van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003;13:169-72. (Pubitemid 36324246)
31. Knadler MP, Lobo E, Chappell J, et al. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2011;50:281-94.
32. Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, et al. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest 2011;139:1130-9.
33. Wahawisan J, Kolluru S, Nguyen T, et al. Methadone toxicity due to smoking cessation-a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. Ann Pharmacother 2011;45:e34.
34. Iqbal J, Sun L, Cao J, et al. Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. Proc Natl Acad Sci USA 2013;110:11115-20.
35. Callaghan JT, Bergstrom RF, Ptak LR, et al. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-93.
36. Remington G, Agid O, Foussias G, et al. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) 2013;225:505-18.
37. Li LJ, Shang DW, Li WB, et al. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. Acta Pharmacol Sin 2012;33:1409-16.
38. Weiss U, Marksteiner J, Kemmler G, et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 2005;25:570-4. (Pubitemid 41669052)
39. Haring C, Fleischhacker WW, Schett P, et al. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990;147:1471-5. (Pubitemid 20365435)
40. Diaz FJ, de Leon J, Josiassen RC, et al. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res 2005;72:131-5. (Pubitemid 39550984)
41. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008;41:81-91. (Pubitemid 351796981)
42. Ng W, Uchida H, Ismail Z, et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit 2009;31:360-6.
43. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003;25:46-53. (Pubitemid 36139825)
44. Lee ST, Ryu S, Kim SR, et al. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol 2012;32:441-8.
45. Theisen FM, Haberhausen M, Schulz E, et al. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 2006;28:750-9. (Pubitemid 44967654)
46. Patel MX, Bowskill S, Couchman L, et al. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009. J Clin Psychopharmacol 2011;31:411-17.
47. Soderberg MM, Haslemo T, Molden E, et al. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. Pharmacogenomics J 2013;13:544-50.
48. Botts S, Diaz FJ, Santoro V, et al. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1453-8.
49. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004;37:63-8. (Pubitemid 38651019)
50. Soderberg MM, Dahl ML. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics 2013;14:1319-36.
51. Plowchalk DR, Rowland Yeo K. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol 2012;68:951-60.
52. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009;39:1591-602.